The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Rhythm Pharmaceuticals Inc shares valued at $371,850 were sold by Cramer Pamela J. on Dec 11 ’25. At $111.00 per share, Cramer Pamela J. sold 3,350 shares. The insider’s holdings dropped to 20,814 shares worth approximately $2.33 million following the completion of this transaction.
Also, PAMELA CRAMER purchased 3,350 shares, netting a total of over 350,980 in proceeds.
Before that, Cramer Pamela J. had sold 3,350 shares from its account. In a trade valued at $351,750, the Chief Human Resources Officer traded Rhythm Pharmaceuticals Inc shares for $105.00 each. Upon closing the transaction, the insider’s holdings decreased to 3,350 shares, worth approximately $2.33 million.
As published in their initiating research note from Citigroup on November 25, 2025, Rhythm Pharmaceuticals Inc [RYTM] has been a Buy and the price target has been revised to $136. Analysts at Oppenheimer downgraded the stock from ‘”an Outperform”‘ to ‘”a Perform”‘ outlook in a report released in early November. As of July 10, 2025, Goldman has initiated its “Buy” rating for RYTM. Earlier on July 07, 2025, Leerink Partners initiated its rating. Their recommendation was “an Outperform” for RYTM stock.
Analyzing RYTM Stock Performance
On last trading session, Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] plunged -0.52% to $111.86. The stock’s lowest price that day was $110.09, but it reached a high of $115.05 in the same session. During the last five days, there has been a surge of approximately 6.77%. Over the course of the year, Rhythm Pharmaceuticals Inc shares have jumped approximately 102.50%. Shares of the company reached a 52-week high of $122.20 on 12/11/25 and a 52-week low of $45.90 on 04/07/25.
Support And Resistance Levels for Rhythm Pharmaceuticals Inc (RYTM)
According to the 24-hour chart, there is a support level at 109.55, which, if violated, would cause prices to drop to 107.24. In the upper region, resistance lies at 114.61. The next price resistance is at 117.36. RSI (Relative Strength Index) is 57.01 on the 14-day chart, showing neutral technical sentiment.
Is Rhythm Pharmaceuticals Inc subject to short interest?
Stocks of Rhythm Pharmaceuticals Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.29 million shares to 5.52 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 5.23 million shares. A jump of 5.22% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.57 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.57.
Which companies own the most shares of Rhythm Pharmaceuticals Inc (RYTM)?
In terms of Rhythm Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 141 in the next 12 months, up nearly 25.39% from the previous closing price of $112.45. Analysts anticipate Rhythm Pharmaceuticals Inc stock to reach 157 by 2025, with the lowest price target being 110. In spite of this, 5 analysts ranked Rhythm Pharmaceuticals Inc stock as Buy at the end of 2025. On April 07, 2025, BofA Securities assigned a price target of “a Buy” to the stock and upgraded coverage with a $63.
